KR950002763A - 쇼크를 치료하기 위한 피리미돈 및 이미다졸리논 - Google Patents

쇼크를 치료하기 위한 피리미돈 및 이미다졸리논 Download PDF

Info

Publication number
KR950002763A
KR950002763A KR1019940016686A KR19940016686A KR950002763A KR 950002763 A KR950002763 A KR 950002763A KR 1019940016686 A KR1019940016686 A KR 1019940016686A KR 19940016686 A KR19940016686 A KR 19940016686A KR 950002763 A KR950002763 A KR 950002763A
Authority
KR
South Korea
Prior art keywords
hydrogen
compound
alkyl
tricycloalkyl
bicycloalkyl
Prior art date
Application number
KR1019940016686A
Other languages
English (en)
Inventor
엘. 코한 빅토리아
알. 페티퍼 에릭
Original Assignee
알렌 제이. 스피겔
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렌 제이. 스피겔, 화이자 인코포레이티드 filed Critical 알렌 제이. 스피겔
Publication of KR950002763A publication Critical patent/KR950002763A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

하기 일반식의 화합물 및 그의 약학적으로 허용되는 산 부가염은 쇼크 및 기타 TNF α-관련 질환을 치료하는데 유용하다;
상기식에서, X는 O 또는 NH이고, m은 0,1 또는 2이며, n은 0,1 또는 2이고, m 및 n은 1 또는 2이며, R1은 C7내지 C11트리사이클로알킬 또는 C7내지 C11비사이클로알킬이고, R2는 메틸 또는 에틸이며, R3은 수소, C1내지 C3알킬, C2내지 C3알케닐, 벤질 또는 펜에틸이고, 및 R4는 수소, C1내지 C3알킬 또는 C2내지 C3알카노일이나, 단, m+n이 1이면, m은 0이고 n은 1이며, m+n이 2이면, R3및 R4는 각각 수소이다.

Description

쇼크를 치료하기 위한 피리미돈 및 이미다졸리논
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 종양 괴사 인자 알파(TNF α)의 생산을 억제하고자 하는 환자에게 염기성 질소 원자를 갖는 하기 일반식의 화합물 또는 그의 약학적으로 허용되는 산 부가염을 상기 치료에 충분한 양으로 투여함을 포함하는 종양 괴사 인자 알파의 생산을 억제하는 방법.
    상기식에서, X는 O 또는 NH이고, m은 0,1 또는 2이며, n은 0,1 또는 2이고, m 및 n은 1 또는 2이며, R1은 C7내지 C11트리사이클로알킬 또는 C7내지 C11비사이클로알킬이고, R2는 메틸 또는 에틸이며, R3은 수소, C1내지 C3알킬, C2내지 C3알케닐, 벤질 또는 펜에틸이고, 및 R4는 수소, C1내지 C3알킬 또는 C2내지 C3알카노일이나, 단, m+n이 1이면, m은 0이고 n은 1이며, m+n이 2이면, R3및 R4는 각각 수소이다.
  2. 제1항에 있어서, 상기 화합물이 5-(3-〔(2S)-엑소비사이클로〔2.2.1〕헵트-2-일옥시〕-4-메톡시페닐)-3,4,5,6-테트라하이드로피리미딘-2(1H)-온인 방법.
  3. 쇼크를 치료하고자 하는 환자에게 염기성 질소 원자를 갖는 하기 일반식의 화합물 또는 그의 약학적으로 허용되는 산 부가염을 상기 치료에 충분한 양으로 투여함을 포함하는 쇼크를 치료하는 방법;
    상기식에서, X는 O 또는 NH이고, m은 0,1 또는 2이며, n은 0,1 또는 2이고, m 및 n은 1 또는 2이며, R1은 C7내지 C11트리사이클로알킬 또는 C7내지 C11비사이클로알킬이고, R2는 메틸 또는 에틸이며, R3은 수소, C1내지 C3알킬, C2내지 C3알케닐, 벤질 또는 펜에틸이고, 및 R4는 수소, C1내지 C3알킬 또는 C2내지 C3알카노일이나, 단, m+n이 1이면, m은 0이고 n은 1이며, m+n이 2이면, R3및 R4는 각각 수소이다.
  4. 제3항에 있어서, 상기 화합물이 5-(3-〔(2S)-엑소비사이클로〔2.2.1〕헵트-2-일옥시〕-4-메톡시페닐)-3,4,5,6-테트라하이드로피리미딘-2(1H)-온인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940016686A 1993-07-13 1994-07-12 쇼크를 치료하기 위한 피리미돈 및 이미다졸리논 KR950002763A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/091,693 US5482944A (en) 1993-07-13 1993-07-13 Pyrimidones and imidazolinones for treatment of shock
US08/091,693 1993-07-13

Publications (1)

Publication Number Publication Date
KR950002763A true KR950002763A (ko) 1995-02-16

Family

ID=22229174

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940016686A KR950002763A (ko) 1993-07-13 1994-07-12 쇼크를 치료하기 위한 피리미돈 및 이미다졸리논

Country Status (12)

Country Link
US (1) US5482944A (ko)
EP (1) EP0636369A1 (ko)
JP (1) JP2899861B2 (ko)
KR (1) KR950002763A (ko)
CN (1) CN1105858A (ko)
AU (1) AU6741294A (ko)
CA (1) CA2127735A1 (ko)
HU (1) HUT67598A (ko)
IL (1) IL110243A0 (ko)
MX (1) MX9405318A (ko)
RU (1) RU94026088A (ko)
ZA (1) ZA945032B (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3315797A1 (de) * 1983-04-30 1984-10-31 Beiersdorf Ag, 2000 Hamburg Substituierte phenyl-2-(1h)-pyrimidinone, verfahren zu ihrer herstellung und ihre verwendung sowie diese verbindungen enthaltende zubereitungen
US4971959A (en) * 1987-04-14 1990-11-20 Warner-Lambert Company Trisubstituted phenyl analogs having activity for congestive heart failure
HU215441B (hu) * 1989-11-13 1999-04-28 Pfizer Inc. Eljárás az endo-biciklo [2.2.1]-heptan-2-ol előállítására és az ebből kapott hatóanyagok enzimatikus úton történő elválasztására
WO1991007177A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
IE913855A1 (en) * 1990-11-06 1992-05-22 Smithkline Beecham Corp Imidazolidinone compounds

Also Published As

Publication number Publication date
ZA945032B (en) 1996-01-12
JPH08208473A (ja) 1996-08-13
CA2127735A1 (en) 1995-01-14
HUT67598A (en) 1995-04-28
IL110243A0 (en) 1994-10-21
AU6741294A (en) 1995-01-27
CN1105858A (zh) 1995-08-02
HU9402081D0 (en) 1994-09-28
EP0636369A1 (en) 1995-02-01
JP2899861B2 (ja) 1999-06-02
MX9405318A (es) 1995-01-31
US5482944A (en) 1996-01-09
RU94026088A (ru) 1996-05-20

Similar Documents

Publication Publication Date Title
WO1999025686B1 (en) Cyclic amine derivatives and their use as drugs
KR950010888A (ko) 평활근세포 증식 및 재발협착증을 억제하는 방법
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
GEP20032958B (en) Adenosine Derivatives
DE3860960D1 (de) Arylcyclobutylalkylamin-derivat zur behandlung von morbus parkinson.
EP1862458A3 (en) Therapeutic agents useful for treating pain
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
RU2000123169A (ru) Бензотиадиазолы и их производные
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
RU94044489A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования миелопероксидазной активности
KR950702554A (ko) 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents)
KR950002763A (ko) 쇼크를 치료하기 위한 피리미돈 및 이미다졸리논
MXPA04004826A (es) Antagonista del receptor de quimioquinas y metodos para su uso.
KR950702544A (ko) 비페닐메탄 유도체 및 이를 함유하는 약제
KR900701262A (ko) 췌장염 등에 대한 치료제
RU98122110A (ru) Пиридил- и пиримидил-пиперазины в лечении болезней, вызываемых злоупотреблением лекарственными и/или наркотическими веществами
KR950016728A (ko) 여성에서 다모증 및 탈모증을 억제하는 방법
KR950703341A (ko) 항부정맥제
RU94036762A (ru) Гетероарилпиперидины, способ их получения, промежуточные соединения синтеза и фармацевтическая композиция
RU99118510A (ru) Композиция для лечения или предупреждения рака простаты
KR870001153A (ko) 디페녹시에틸아민 유도체가 함유된 약제조성물 및 그의 생산방법
KR950008483A (ko) 퀴놀린 화합물
KR920011486A (ko) 항종양제
KR900014360A (ko) 피리딘카복실산 아미드 유도체 및 이를 함유하는 약학 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application